Epstein-Barr Virus Market Likely to Exhibit Substantial Growth by 2032, Examines DelveInsight | Key Players in the Market - Viracta, Atara, AlloVir, ModernaTX, Immunitas, Schrödinger, VelosBio, Takeda, Gilead, Merck

The dynamics of the Epstein–Barr virus (EBV) market are anticipated to change during the forecast period (2023–2032) owing to the launch of novel therapies in clinical development and the development of basic research, clinical medicine, and new ideas related to the pathogenesis and clinical aspects of EBV-associated diseases.

New York, USA, Oct. 02, 2023 (GLOBE NEWSWIRE) -- *Epstein-Barr Virus Market Likely to Exhibit Substantial Growth by 2032, Examines DelveInsight | Key Players in the Market - Viracta, Atara, AlloVir, ModernaTX, Immunitas, Schrödinger, VelosBio, Takeda, Gilead, Merck *

*The dynamics of the Epstein–Barr virus (EBV) market are anticipated to change during the forecast period (2023–2032) owing to the launch of novel therapies in clinical development and the development of basic research, clinical medicine, and new ideas related to the pathogenesis and clinical aspects of EBV-associated diseases.*

DelveInsight’s *Epstein-Barr Virus Market Insights* report includes a comprehensive understanding of current treatment practices, Epstein-Barr virus emerging drugs, market share of individual therapies, and current and forecasted Epstein-Barr virus market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

*Key Takeaways from the Epstein-Barr Virus Market Report*

· As per DelveInsight’s analysis, the Epstein-Barr virus market size was found to be *USD 1.6 billion* in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, in 2021, the total diagnosed incident cases of EBV-IM was more than *1 million* in the 7MM. The highest number of cases was seen in the US, i.e., about *416K*. EU4 and the UK accounted for more than *557K* cases.  
· Leading Epstein-Barr virus companies such as *Viracta Therapeutics, Atara Biotherapeutics, AlloVir, ModernaTX, Inc., Immunitas Therapeutics, Schrödinger, Inc., VelosBio Inc., Takeda, VelosBio Inc., Gilead Sciences, Millennium Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Acerta Pharma BV, medac GmbH, Bristol-Myers Squibb, *and others are developing novel Epstein-Barr virus drugs that can be available in the Epstein-Barr virus market in the coming years.
· Some of the key therapies for Epstein-Barr virus treatment include *Nanatinostat (VRx-3996) in Combination With valganciclovir, EBVALLO (tabelecleucel), Posoleucel (viralym-M; ALVR-105), mRNA-1189, IMT-009, SGR-1505, Zilovertamab vedotin, 19(T2)28z1xx CAR T cells**, *and others. 
· In *December 2022, Atara Biotherapeutics* announced updated interim analysis and safety results from its Phase III multicenter ALLELE study investigating tabelecleucel (tab-cel) to treat relapsed/refractory (R/R) EBV+ PTLD following SOT or HCT.
· In *December 2022,* *AlloVir *announced positive final results in phase II posoleucel multi-virus prevention study in an oral presentation at the 64th ASH Annual Meeting and Exposition.
· In *October 2022,* the CHMP adopted a positive opinion, recommending granting marketing authorization under exceptional circumstances for the medicinal product EBVALLO, intended to treat EBV+ PTLD. 
· In *September 2022, Viracta Therapeutics* announced that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to nanatinostat and valganciclovir (nana-val), to treat peripheral T-cell lymphoma (PTCL).

Discover which therapies are expected to grab the major EBV market share @ *Epstein-Barr Virus Market Report*

*Epstein-Barr Virus Overview*

Epstein-Barr virus (EBV), a prevalent virus, typically remains inactive in the majority of individuals. It is responsible for causing infectious mononucleosis and has been linked to various cancers, including Burkitt lymphoma, immunoblastic lymphoma, nasopharyngeal cancer, and gastric cancer. EBV can be transmitted through multiple routes, such as deep kissing or sharing food. After the initial infection, elevated levels of viral DNA can be detected in saliva. Additionally, children may become infected by consuming food already chewed by an individual with EBV. Transmission has also been reported through stem cell transplantation, organ transplants, and blood transfusions.

The clinical manifestation of EBV infection often shares similarities with other acute viral syndromes triggered by different viruses, including Cytomegalovirus (CMV) and hepatitis viruses. Consequently, similar symptoms can be observed. Diagnostic approaches for EBV vary depending on the patient’s immune status. The significance and urgency of therapeutic measures differ between immunocompromised and immunocompetent individuals, leading to the utilization of a diverse array of tests for EBV diagnosis.

*Epstein-Barr Virus Epidemiology Segmentation*

The EBV epidemiology section provides insights into the historical and current EBV patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The *EBV market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

· Total Diagnosed Incident Cases of EBV-IM 
· Total Incident Cases of EBV+ Cancers and PTLD 
· Incident Cases of EBV+ Cancers
· Incident Cases of EBV+ PTLD  

Download the report to understand which factors are driving Epstein-Barr virus epidemiology trends @ *Epstein-Barr Virus Epidemiological Insights*

*Epstein-Barr Virus Treatment Market *

Symptomatic treatment is the primary approach for managing EBV, with medications aimed at alleviating fever and pain. Although certain studies have explored the use of antiviral drugs for EBV, they have demonstrated a reduction in viral shedding in the oral cavity without a significant improvement in overall symptoms. In cases of airway compromise or autoimmune complications arising from EBV infection, corticosteroids may offer some benefits to patients.

Researchers have examined both intravenous (IV) and oral forms of acyclovir as potential treatments for infectious mononucleosis. *Valacyclovir*, which is a prodrug of acyclovir, offers an oral bioavailability of at least 50%, in contrast to the 10–20% bioavailability of the parent compound. Additionally, *ganciclovir *has demonstrated in vitro activity against Epstein-Barr virus (EBV), and either ganciclovir or its oral prodrug, *valganciclovir*, has been employed to prevent post-transplant EBV-related diseases.

The prophylactic use of *Rituximab-induced B-cell depletion post-HSCT* proves effective in managing EBV-DNAemia. This treatment targets CD20+ B cells, which experience increased proliferation in the presence of the virus, leading to the removal of the EBV reservoir. For patients at risk of rapid disease progression and clinical deterioration, it is imperative to initiate treatment promptly. In accordance with the ECIL-6 guidelines, the first-line approach for EBV-positive PTLD is rituximab monotherapy, with a standard weekly dose of 375 mg/m2.

Learn more about the FDA-approved drugs for EBV @ *Drugs for* *Epstein-Barr Virus** Treatment*

*Key Epstein-Barr Virus Therapies and Companies*

· Nanatinostat (VRx-3996) in Combination With valganciclovir: Viracta Therapeutics
· EBVALLO (tabelecleucel): Atara Biotherapeutics
· Posoleucel (viralym-M; ALVR-105): AlloVir
· mRNA-1189: ModernaTX, Inc.
· IMT-009: Immunitas Therapeutics
· SGR-1505: Schrödinger, Inc.
· Zilovertamab vedotin: VelosBio Inc.
· 19(T2)28z1xx CAR T cells: Takeda

To know more about EBV clinical trials, visit @ *Epstein-Barr Virus Treatment Drugs*

*Epstein-Barr Virus Market Dynamics*

The dynamics of the Epstein-Barr virus market are expected to change in the coming years. *Advancements in fundamental research, clinical medicine, and innovative concepts* concerning the development and clinical features of diseases associated with EBV have come to light. *International collaboration *among registries is enhancing the effectiveness and caliber of treatments for EBV-linked tumors. The use of *EBV-specific cytotoxic T-cell infusions* has demonstrated efficacy in EBV-related post-transplant lymphoproliferative disorder (EBV-PTLD), and the expansion of such adoptive immunotherapies to address other EBV-related malignancies is an actively pursued avenue of research. Moreover, the *growing prevalence and improved diagnostic capabilities* of these conditions are expected to generate substantial revenue in the future.

Furthermore, many potential therapies are being investigated for the treatment of Epstein-Barr Virus, and it is safe to predict that the treatment space will significantly impact the Epstein-Barr Virus market during the forecast period. In addition, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the Epstein-Barr Virus market in the 7MM.

However, several factors are impeding the growth of the Epstein-Barr virus market. The *underlying mechanisms* behind the virologic and immunologic events during the extended incubation period remain uncertain. Identifying *EBV+ cells* can be challenging, and their detailed phenotype assessment using conventional immunohistochemistry methods can prove elusive. *Scarce data on the economic and societal impact* of infectious mononucleosis hinders the evaluation of the* cost-effectiveness* of a preventive vaccine. EBV-induced diseases can lead to severe illness and even fatalities.

Furthermore, the Epstein-Barr virus market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the Epstein-Barr virus market growth.

*Epstein-Barr Virus Report Metrics* *Details*
Study Period 2019–2032
Epstein-Barr Virus Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Epstein-Barr Virus Market Size in 2021 USD 1.6 Billion
Key Epstein-Barr Virus Companies Viracta Therapeutics, Atara Biotherapeutics, AlloVir, ModernaTX, Inc., Immunitas Therapeutics, Schrödinger, Inc., VelosBio Inc., Takeda, VelosBio Inc., Gilead Sciences, Millennium Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Acerta Pharma BV, medac GmbH, Bristol-Myers Squibb, and others
Key Epstein-Barr Virus Therapies Nanatinostat (VRx-3996) in Combination With valganciclovir, EBVALLO (tabelecleucel), Posoleucel (viralym-M; ALVR-105), mRNA-1189, IMT-009, SGR-1505, Zilovertamab vedotin, 19(T2)28z1xx CAR T cells, and others

*Scope of the **Epstein-Barr Virus** Market Report*

· *Therapeutic Assessment: *Epstein-Barr Virus current marketed and emerging therapies
· *Epstein-Barr Virus* *Market Dynamics:* Attribute Analysis of Emerging Epstein-Barr Virus Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Epstein-Barr Virus Market Access and Reimbursement*

Discover more about Epstein-Barr virus drugs in development @ *Epstein-Barr Virus Clinical Trials*

*Table of Contents*

1. Epstein-Barr Virus Market Key Insights
2. Epstein-Barr Virus Market Report Introduction
3. Epstein-Barr Virus Market Overview at a Glance
4. Epstein-Barr Virus Market Executive Summary
5. Disease Background and Overview
6. Epstein-Barr Virus Treatment and Management
7. Epstein-Barr Virus Epidemiology and Patient Population
8. Patient Journey
9. Epstein-Barr Virus Marketed Drugs
10. Epstein-Barr Virus Emerging Drugs
11. Seven Major Epstein-Barr Virus Market Analysis
12. Epstein-Barr Virus Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Related Reports*

*Epstein-Barr Virus Epidemiology Forecast*

*Epstein-Barr Virus Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted Epstein-Barr virus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*Epstein-Barr Virus Pipeline*

*Epstein-Barr Virus Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Epstein-Barr virus companies, including *Viracta Therapeutics, Atara Biotherapeutics, AlloVir, ModernaTX, Inc., Immunitas Therapeutics, Schrödinger, Inc., VelosBio Inc., Takeda, VelosBio Inc., Gilead Sciences, Millennium Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Acerta Pharma BV, medac GmbH, Bristol-Myers Squibb**,  *among others.

*Relapsed/Refractory Epstein Barr Virus Market*

*Relapsed/Refractory Epstein Barr Virus Market Insights, Epidemiology, and Market Forecast **– 2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key R/R EBV companies including *AlloVir, ModernaTX, Inc., Immunitas Therapeutics, Schrödinger, Inc., VelosBio Inc., Takeda, Merck Sharp & Dohme LLC, Acerta Pharma BV, medac GmbH, Bristol-Myers Squibb**, *among others.

*Relapsed/Refractory Epstein Barr Virus Pipeline*

*Relapsed/Refractory Epstein Barr Virus Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key R/R EBV companies, including *VelosBio Inc., Takeda, VelosBio Inc., Gilead Sciences, Millennium Pharmaceuticals, Inc., Merck Sharp & Dohme LLC**, *among others.

*Relapsed/Refractory Epstein Barr Virus Epidemiology Forecast*

*Relapsed/Refractory Epstein Barr Virus Epidemiology Forecast **– 2032* report delivers an in-depth understanding of the disease, historical and forecasted R/R EBV epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*Other Trending Reports*

*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Frontotemporal Dementia Pipeline** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market *

*Related Healthcare Services*

*Healthcare Consulting*

*Healthcare Competitive Intelligence Services*

*Healthcare Asset Prioritization Services*

*About DelveInsight*

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*

*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com